Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan King

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Neuro-Oncology|May 25, 2007
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic miceMichael A Badruddoja, Stephen T Keir, Ivan King, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 13, 2009
An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymesAlaa-Eldin F Nassar, Ivan King, Brandy L Paris, et al.
Human Gene Therapy|July 23, 2002
Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agentIvan King, David Bermudes, Stanley Lin, et al.
The Oncologist|June 28, 2025
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumorsApostolia M Tsimberidou, Farshid Dayyani, David Sommerhalder, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Neuro-Oncology|May 25, 2007
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic miceMichael A Badruddoja, Stephen T Keir, Ivan King, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 13, 2009
An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymesAlaa-Eldin F Nassar, Ivan King, Brandy L Paris, et al.
Human Gene Therapy|July 23, 2002
Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agentIvan King, David Bermudes, Stanley Lin, et al.
The Oncologist|June 28, 2025
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumorsApostolia M Tsimberidou, Farshid Dayyani, David Sommerhalder, et al.
Leukemia Research|February 16, 2006
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndromeKaren W L Yee, Jorge Cortes, Alessandra Ferrajoli, et al.
Pageof 2